Aerie Pharmaceuticals' eye drop succeeds in late-stage study

(Reuters) - Drugmaker Aerie Pharmaceuticals Inc said on Wednesday its experimental eye drop met the main goal of a late-stage study, sending its shares up as much as 65 percent in extended trading.